Regeneron Pharmaceuticals, Inc. EV/EBITDA
Data as of June 01, 2026
EV/EBITDA
12.89
Enterprise Value
$56.50B
EBITDA (TTM)
$4.38B
Sector
Healthcare
How It's Calculated
12.89 = $56.50B ÷ $4.38B
What This Means
Regeneron Pharmaceuticals, Inc.'s EV/EBITDA of 12.9 is in a moderate range for Healthcare.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare sector, specifically in Biotechnology. With a market capitalization of about $64.45B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $614.78, within a 52-week range of $476.49 to $821.11 (-25.1% from the high, +29.0% from the low). Beta of 0.30 indicates relatively lower volatility versus the market.
Trailing profit margin is about 29.6%, signaling a strong profit margin relative to many peers.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Regeneron Pharmaceuticals, Inc., the ratio should be read with growth, capex needs, and cycle position in Healthcare. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 12.89x EV/EBITDA, Regeneron Pharmaceuticals, Inc. (REGN) carries a mid-range EV/EBITDA multiple that investors often stack-rank within the sector. Enterprise value of about $56.50B and EBITDA near $4.38B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the REGN metrics hub for related valuation pages.
Sector Comparison
Among Healthcare names on our S&P 100 coverage, Regeneron Pharmaceuticals, Inc.'s EV/EBITDA of 12.89 can be compared with peers such as LLY (28.26), JNJ (16.76), UNH (18.61). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.
Key Takeaways
- REGN is grouped in the Healthcare sector for peer comparisons.
- Recent beta of 0.30 suggests lower-than-market price sensitivity.
- Trailing profit margin of 29.6% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for REGN.
Other REGN Metrics
Frequently Asked Questions
What is REGN's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Regeneron Pharmaceuticals, Inc.'s ratio is about 12.89 — common for comparing leveraged companies in Healthcare.
Is 12.89 high or low vs peers?
Among Healthcare peers (e.g. LLY (28.26), TMO (19.75), UNH (18.61)), REGN's 12.89 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →